PIK3CA

未知生产厂商

PIK3CA is under investigation in clinical trial NCT02957266 (Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy).

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

PIK3CA is under investigation in clinical trial NCT02957266 (Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy).

技术标识符

UNII ID: JQ83GG8LT2

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

BYL719 (alpelisib) for use in the treatment of PIK3CA-related overgrowth spectrum (pros-CLOVES syndrome)
US 11433059 B2申请人: INST NAT SANTE RECH MED优先权: 2016
CN
EP
US
WO
11 件公开
Mutations of the PIK3CA gene in human cancers
US 8026053 B2申请人: UNIV JOHNS HOPKINS优先权: 2005
US
8 件公开
APPLICATION OF PYRIDO[1,2-A]PYRIMIDINONE ANALOG
US 2024075038 A1申请人: GUANGZHOU JOYO PHARMATECH CO LTD优先权: 2021
CN
EP
US
WO
6 件公开
T CELL RECEPTORS TARGETING PIK3CA MUTATIONS AND USES THEREOF
- EP 3986450 A4
  申请人: MEMORIAL SLOAN KETTERING CANCER CENTER优先权: 2019
  CN
  EP
  US
  WO
  5 件公开
- EP 4656196 A3
  申请人: MEMORIAL SLOAN KETTERING CANCER CENTER优先权: 2018
  EP
  US
  3 件公开
CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS
EP 3082957 B1申请人: BIOMED VALLEY DISCOVERIES INC优先权: 2013
EP
US
WO
5 件公开
RNA antagonist compounds for the modulation of PIK3CA expression
US 7863437 B2申请人: ENZON PHARMACEUTICALS INC优先权: 2008
CN
US
5 件公开
BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND
EP 3009424 B1申请人: ASTELLAS PHARMA INC优先权: 2013
CN
EP
US
WO
4 件公开
METHODS OF TREATING CANCER WITH PI3K INHIBITOR, GDC-0077
EP 3826622 A1申请人: HOFFMANN LA ROCHE优先权: 2018
CN
EP
US
4 件公开
Combination therapy comprising a B-Raf inhibitor and a second inhibitor
CN 105209073 A申请人: NOVARTIS AG优先权: 2013
CN
US
4 件公开
NOVEL ENTEROCOCCUS FAECIUM LCM001 STRAIN, AND USE THEREOF
US 2024408152 A1申请人: MBIOMETHERAPEUTICS CO LTD优先权: 2021
EP
US
WO
3 件公开

药物

PIK3CA

概览

专利

T CELL RECEPTORS TARGETING PIK3CA MUTATIONS AND USES THEREOF